Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Leveraging Gold Nanostars for Precision Laser Interstitial Thermal Therapy

News

June 25, 2024
PRESS RELEASE: On June 14, 2024, a new editorial was published in Oncotarget, entitled, “Leveraging gold nanostars for precision laser interstitial thermal therapy.” continue reading »

Impact of Dual Immunotherapies Before Surgery in HR+/HER2-negative Breast Cancer

Oncotarget

June 20, 2024
In this new study, researchers assessed the feasibility of treating HR+/HER2-negative breast cancer patients with the immunotherapies durvalumab and tremelimumab before standard neoadjuvant chemotherapy and surgery. continue reading »

Assessment of Serum Tumor Markers CEA, CA-125, and CA19-9 as Adjuncts in Non-small Cell Lung Cancer Management

News

June 19, 2024
PRESS RELEASE: On June 13, 2024, a new research paper was published in Oncotarget, entitled, “Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management.” continue reading »

When Does a Melanoma Metastasize? Implications for Management

News

June 18, 2024
PRESS RELEASE: On June 13, 2024, a new research perspective was published in Oncotarget, entitled, “When does a melanoma metastasize? Implications for management.” continue reading »

Dr. Blagosklonny’s Strategy: From Osimertinib to Preemptive Combinations

Oncotarget

June 6, 2024
This article dissects Dr. Mikhail V. Blagosklonny’s paradigm-shifting perspective on preemptive combinations for treating EGFR-mutant non-small cell lung cancer. continue reading »